Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) subsidiary Guangzhou Baiyunshan Zhongyi Pharmaceutical received an updated drug manufacturing license from the Guangdong Provincial Drug Administration in China, according to a Wednesday filing with the Shanghai bourse.
The updated license covers the change of the person in charge of production, as well as the removal of a production facility.
The changes will not affect Zhongyi Pharmaceutical's production.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.